Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies

Todd Schlesinger; Neal Bhatia; Brian Berman; Ayman Grada; Albert Torra; David Cutler; Mark Lebwohl

doi:10.25251/skin.4.supp.120

Todd Schlesinger

Dermatology and Laser Centre of Charleston, Charleston, SC

Neal Bhatia

Therapeutics Clinical Research, San Diego, CA

Brian Berman

Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL

Ayman Grada

Almirall, Exton, PA

Albert Torra

Almirall, Barcelona, Spain

David Cutler

Athenex, Inc., Buffalo, NY

Mark Lebwohl

Icahn School of Medicine at Mount Sinai, New York, NY

Keywords

Skin Cancer, Actinic Keratosis, Src Kinase Inhibitor, Tirbanbulin, Safety

Abstract

Abstract not available.

References

References not available.

Poster PDF

Published

Oct 27, 2020

DOI https://doi.org/10.25251/skin.4.supp.120

How to Cite

Schlesinger, T., Bhatia, N., Berman, B., Grada, A., Torra, A., Cutler, D., & Lebwohl, M. (2020). Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies. SKIN The Journal of Cutaneous Medicine, 4(6), s120. https://doi.org/10.25251/skin.4.supp.120

Issue

Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)

Section

Skin Cancer

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Matthias Augustin, Jolanta Weglowska, Mark Lebwohl, Carle Paul, Vincent Piquet, Howard Sofen, Andrew Blauvelt, Daniel Burge, Luke Peterson, Janice Drew, Robert Rollen, Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT) , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Laura K Ferris, April W Armstrong, James Del Rosso, Zoe D Draelos, Melinda Gooderham, Mark Lebwohl, Kim A Papp, Jennifer Soung, Linda Stein Gold, David Krupa, Robert C Higham, Patrick Burnett, David R Berk, Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2) , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Kristian Reich, Mark Lebwohl, Carle Paul, Mads Ropke, Monika Rosen, Klaus Hansen, Brodalumab, a Human Anti-Interleukin-17 Receptor A Monoclonal Antibody, Shows Low Immunogenicity in Patients with Moderate-to-Severe Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
April W. Armstrong, Mark Lebwohl, Jerry Bagel, Todd Schlesinger, Subhashis Banerjee, Renata M. Kisa, Thomas Scharnitz, Kim Hoyt, Bruce Strober, Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Andrew Blauvelt, Kristian Reich, Mark Lebwohl, Daniel Burge, Catherine Arendt, Luke Peterson, Robert Rolleri, Alice Gottlieb, Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Overview of 3 Randomized Controlled Trials , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Hilary Baldwin, Emmy Graber, Richard G Fried, Evan A Rieder, Julie C Harper, Andrew F Alexis, Linda Stein Gold, Adelaide A Hebert, James Del Rosso, Leon Kircik, Ayman Grada, Siva Narayanan, Volker Koscielny, Ismail Kasujee, An Expert Panel Questionnaire for Assessing Patient-Reported and Caregiver-Reported Outcomes in Acne Vulgaris , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Athanasios Tsianakas, Neal Bhatia, Shanavas Alikunju, Anirudh Gautam, Srinivas Shenoy, Preeti Singh, Srinivas Sidgiddi, DFD-29, a low dose oral minocycline, demonstrates superior efficacy as compared to placebo and Oraycea ® Capsules (doxycycline HCl) in subjects with papulopustular rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Mark Lebwohl, Michael Bukhalo, Linda Stein Gold, Michelle Pelle, Bradley Glick, Mar Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Kevin Douglas, Greg St. John, Ramon Espaillat, Robert Bissonnette, A Phase 3b Study Evaluating Safety and Efficacy of Risankizumab in Adult Patients with Moderate-to-Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Darrell Rigel, Mark Lebwohl, Todd Schlesinger, April Armstrong, Brian Berman, Neal Bhatia, James Del Rosso, Leon Kircik, Vishal A. Patel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Impact of Actinic Keratosis on patient-reported AK symptoms, emotions and functioning measured using Skindex-16, among patients with Actinic Keratosis administered tirbanibulin in real-world community practices across the U.S. (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Fran E Cook-Bolden, MD, Linda Stein Gold, MD, Hilary Baldwin, MD, Valerie Callender, MD, Andrew F Alexis, MD, MPH, Neal Bhatia, MD, Joshua A Zeichner, MD, Emil A Tanghetti, MD, Eric Guenin, PharmD, PhD, MPH, Safety of Tazarotene 0.045% Lotion and Hyperpigmentation Improvements in Black Participants With Moderate-to-Severe Acne , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23

<< < 5 6 7 8 9 10 11 12 13 14 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)